New hope for rare GIST: targeted pill shows promise in early trial
NCT ID NCT07434843
First seen Feb 28, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This phase 2 study tests the drug pemigatinib in 24 people with advanced SDH-deficient GIST, a rare stomach cancer that has spread. The drug is a pill that blocks certain growth signals in cancer cells. Researchers will measure how many patients' tumors shrink and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pemigatinib (a targeted therapy pill that blocks certain growth signals in cancer cells)
What this could lead to
If successful, this could provide a new treatment option for people with a rare type of GIST that has few other choices.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.